

GLAXOSMITHKLINE PLC
Form 6-K
October 17, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 17 October 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Andrew Witty
 - b) Position/status Chief Executive Officer
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Acquisition of Ordinary Shares following the
 - b) Nature of the transaction re-investment of dividends paid to shareholders on 13 October 2016.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£17.0319	25.344
 - d) Aggregated information Aggregated volume Price n/a (single transaction)
 - e) Date of the transaction 2016-10-13
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	paid to shareholders on 13 October 2016.
c) Price(s) and volume(s)	Price(s) Volume(s) £17.0319 30.656
d) Aggregated information Aggregated volume Price	n/a (single transaction)
e) Date of the transaction	2016-10-13
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr L Debruyne
b) Position/status	President, Global Vaccines
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Acquisition of Ordinary Shares following the
b) Nature of the transaction	re-investment of dividends paid to shareholders on 13 October 2016.
c) Price(s) and volume(s)	Price(s) Volume(s) £17.0319 645.478
d) Aggregated information Aggregated volume Price	n/a (single transaction)
e) Date of the transaction	2016-10-13
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr S Dingemans
b) Position/status	Chief Financial Officer
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882				
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£17.0319</td> <td>111.076</td> </tr> </table>	Price(s)	Volume(s)	£17.0319	111.076
Price(s)	Volume(s)				
£17.0319	111.076				
d) Aggregated information	n/a (single transaction)				
e) Date of the transaction	2016-10-13				
f) Place of the transaction	London Stock Exchange (XLON)				

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S A Hussain
b) Position/status	President, Global Pharmaceuticals
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882				
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£17.0319</td> <td>589.664</td> </tr> </table>	Price(s)	Volume(s)	£17.0319	589.664
Price(s)	Volume(s)				
£17.0319	589.664				
d) Aggregated information	n/a (single transaction)				
e) Date of the transaction	2016-10-13				
f) Place of the transaction	London Stock Exchange (XLON)				

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Acquisition of Ordinary Shares following the
 - b) Nature of the transaction re-investment of dividends paid to shareholders on 13 October 2016.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£17.0319	921.902
 - d) Aggregated information Aggregated volume Price n/a (single transaction)
 - e) Date of the transaction 2016-10-13
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms C Thomas
 - b) Position/status SVP, HR
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Acquisition of Ordinary Shares following the
 - b) Nature of the transaction re-investment of dividends paid to shareholders on 13 October 2016.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

c)	Price(s) and volume(s)	Price(s) £17.0319	Volume(s) 127.956
d)	Aggregated information Aggregated volume Price	n/a (single transaction)	
e)	Date of the transaction	2016-10-13	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr P C Thomson	
b)	Position/status	SVP, Communications & Government Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.	
b)	Nature of the transaction	re-investment of dividends paid to shareholders on 13 October 2016.	
c)	Price(s) and volume(s)	Price(s) £17.0319	Volume(s) 413.464
d)	Aggregated information Aggregated volume Price	n/a (single transaction)	
e)	Date of the transaction	2016-10-13	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr M M Slaoui	
b)	Position/status	Chairman, Global Vaccines	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.			

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.	
c)	Price(s) and volume(s)	Price(s) £17.0319	Volume(s) 1.905
d)	Aggregated information	n/a (single transaction)	
e)	Aggregated volume Price		
e)	Date of the transaction	2016-10-13	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Dr P J T Vallance	
b)	Position/status	President, Pharmaceuticals R&D	
c)	Initial notification/ amendment	Initial notification	

2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.	
c)	Price(s) and volume(s)	Price(s) £17.0319	Volume(s) 1545.793
d)	Aggregated information	n/a (single transaction)	
e)	Aggregated volume Price		
e)	Date of the transaction	2016-10-13	
f)	Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status CEO Designate
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Acquisition of Ordinary Shares following the
 - b) Nature of the transaction re-investment of dividends paid to shareholders on 13 October 2016.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£17.0319	1211.674
 - d) Aggregated information Aggregated volume Price n/a (single transaction)
 - e) Date of the transaction 2016-10-13
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mrs K Thomson
PCA of Mr P C Thomson
 - b) Position/status (SVP, Communications & Government Affairs)
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

		paid to shareholders on 13 October 2016.	
c)	Price(s) and volume(s)	Price(s) £17.0319	Volume(s) 101.411
d)	Aggregated information Aggregated volume Price	n/a (single transaction)	
e)	Date of the transaction	2016-10-13	
f)	Place of the transaction	London Stock Exchange (XLON)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: October 17, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc